
Articles
-
Oct 11, 2023 |
finance.yahoo.com | Jameelah Robinson
(Bloomberg) -- Medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs are poised to extend a precipitous drop into year end.
-
Oct 11, 2023 |
bloomberg.com | Jameelah Robinson
Medical-device stocks hard hit by the rising popularity of a new class of weight loss drugs are poised to extend a precipitous drop into year end. That’s according to JPMorgan Chase & Co. analyst Robbie Marcus , who says the sector will see more declines before sentiment shifts as big-money investors steer clear. “Long-only portfolio managers are just exiting these positions and avoiding the space,” he wrote in a note Wednesday.
-
Sep 21, 2023 |
bloomberg.com | Jameelah Robinson
Wegovy and Ozempic’s owner, Novo Nordisk A/S, has rallied 17% in Copenhagen trading. Photographer: Carsten Snejbjerg/BloombergSeptember 21, 2023 at 9:58 AM EDTUpdated on September 22, 2023 at 2:12 PM EDTHealth-care stocks are heading for their worst annual performance relative to the broader market in almost 25 years as a new class of weight-loss drugs looks set to reorder the market for a host of existing profitable treatments. The group — which includes the likes of Pfizer Inc.
-
Aug 30, 2023 |
news.bloomberglaw.com | Bre Bradham |Ilya Bañares |Jameelah Robinson
(Updates to add BTIG analyst commentary and latest trading.)Outlook Therapeutics plunges 83% to a record low after saying the US FDA issued a Complete Response Letter to the Biologics License Application, or BLA, for ONS-5010 — an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.
-
Aug 8, 2023 |
mk.bloombergadria.com | Angel Adegbesan |Jameelah Robinson
Берзи 9 август 2023, 07:59 Ентузијазмот на Волстрит за сите нешта поврзани со слабеењето доби нов поттик од вчера, откако резултатите од испитувањето на лекот за слабеење на „Ново Нордиск“ (Novo Nordisk A/S) покажаа придобивки за срцето. Акциите поврзани со лекови за губење на тежината скокнаа и за ривалот „Ели Лили“ (Eli Lilly & Co.) чии акции се пораснаа за 15 отсто до рекордно високо ниво.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →